Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients

Keyphrases

• Immune Checkpoint Blockade 100%
• Cancer Immunotherapy 100%
• T-cell Mediated 100%
• Allograft Rejection 100%
• Checkpoint Inhibitors 100%
• Organ Transplant Patient 100%
• Neglected Population 100%
• Clinical Trials 66%
• Immunosuppression 66%
• Immune Checkpoint Inhibitors 66%
• Organ Transplant Recipients 66%
• Clinical Experience 33%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 33%
• Clinical Data 33%
• Organ Transplant 33%
• Anti-tumor Response 33%
• Combination Therapy 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Transplant Population 33%
• Monotherapy 33%
• Transplant Medicine 33%
• Rapid Growth 33%
• Combinational Therapy 33%
• Risk of Malignancy 33%
• PD-1 Inhibitor 33%
• Advanced Malignancies 33%
• Malignancy-associated 33%
• ITK Inhibitor 33%

Medicine and Dentistry

• Transplantation 100%
• Cancer Immunotherapy 100%
• T Cell 100%
• Graft Rejection 50%
• Immune Checkpoint Blockade 50%
• Immunosuppressive Treatment 33%
• Immune Checkpoint Inhibitor 33%
• Clinical Trial 33%
• Cancer 33%
• Neoplasm 16%
• Combination Therapy 16%
• Monotherapy 16%
• CTLA-4 16%
• Mammalian Target of Rapamycin 16%
• Medicine 16%

Immunology and Microbiology

• Transplant Rejection 100%
• Immune Checkpoint Blockade 100%
• T Cell 100%
• Cancer Immunotherapy 100%
• Immunosuppression 66%
• Immunity 66%
• CTLA-4 33%